title: Uterine sarcoma after tamoxifen therapy for breast cancer.
abstract: Tamoxifen has been shown to significantly reduce the risk of tumour recurrence in women with receptor positive breast cancer and has been used for chemoprevention in women with both non-invasive cancer and those with a high risk of developing breast cancer. An established and accepted risk with this treatment is the increased incidence of adenocarcinoma of the endometrium. Less well recognised is uterine sarcoma, a rare and aggressive tumour accounting for under five percent of uterine malignancies, with five year survival rates in the order of 50%.
authors.affiliation: Department of Radiation Oncology, Cork University Hospital, Wilton, Cork. syaf_83@yahoo.co.uk
authors.forename: Mat
authors.initials: M
authors.lastname: Samuji
authors.forename: R
authors.initials: R
authors.lastname: O'Sullivan
authors.forename: R
authors.initials: R
authors.lastname: Shireen
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000139:chemically induced* / Q000175:diagnosis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen